Wnt/β-catenin signaling in cancers and targeted therapies
Open accessThe DOI matches its Crossref record; 468 of the 468 references it cites were found in a registry or an index.
Abstract
Wnt/β-catenin signaling has been broadly implicated in human cancers and experimental cancer models of animals. Aberrant activation of Wnt/β-catenin signaling is tightly linked with the increment of prevalence, advancement of malignant progression, development of poor prognostics, and even ascendence of the cancer-associated mortality. Early experimental investigations have proposed the theoretical potential that efficient repression of this signaling might provide promising therapeutic choices in managing various types of cancers. Up to date, many therapies targeting Wnt/β-catenin signaling in cancers have been developed, which is assumed to endow clinicians with new opportunities of developing more satisfactory and precise remedies for cancer patients with aberrant Wnt/β-catenin signaling. However, current facts indicate that the clinical translations of Wnt/β-catenin signaling-dependent targeted therapies have faced un-neglectable crises and challenges. Therefore, in this study, we systematically reviewed the most updated knowledge of Wnt/β-catenin signaling in cancers and relatively targeted therapies to generate a clearer and more accurate awareness of both the developmental stage and underlying limitations of Wnt/β-catenin-targeted therapies in cancers. Insights of this study will help readers better understand the roles of Wnt/β-catenin signaling in cancers and provide insights to acknowledge the current opportunities and challenges of targeting this signaling in cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The inactivation of GSK3β disrupts the integrity and function of the destruction complex, thereby preventing β-catenin phosphorylation. As a result, unphosphorylated, stable β-catenin accumulates in the cytoplasm, translocates to the nucleus, and activates the transcription of its target genes, including c-Myc and Cyclin D1 [35, 46, 47, 52–55].”
From PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma (2026) · cites this paper as [54]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Items 201–400 of 468
de la Roche, M., Rutherford, T. J., Gupta, D., Veprintsev, D. B., Saxty, B., Freund, S. M., & Bienz, M. (2012) · Nature Communications · doi:10.1038/ncomms1680 · Cited by 120
RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary
Ryland, G. L., Hunter, S. M., Doyle, M. A., Rowley, S. M., Christie, M., Allan, P. E., Bowtell, D. D., Australian Ovarian Cancer Study Group, Gorringe, K. L., & Campbell, I. G. (2013) · The Journal of Pathology · doi:10.1002/path.4134 · Cited by 119 · cited 1×
“Similarly, Rnf43 mutations were overall found in uterine corpus endometrial carcinoma, stomach adenocarcinoma, colorectal adenocarcinoma, ovarian cancer, and pancreatic ductal adenocarcinoma.(121,122) Znrf3 and Rnf43 were not essential in the intestine but dysregulation of Znrf3/Rnf43 was important for the growth of C…”
BackgroundTargeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia
Salik, B., Yi, H., Hassan, N., Santiappillai, N., Vick, B., Connerty, P., Duly, A., Trahair, T., Woo, A. J., Beck, D., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.05.014 · Cited by 119 · cited 1×
“demonstrated that rosmantuzumab can impair the self-renewal and differentiation of acute myeloid leukemia cells in the PDX model, meanwhile free from influencing normal hematopoietic stem cells.(313) For the clinical trial, a phase 1a/b trial about rosmantuzumab in advanced solid tumors and previously treated metastat…”
BackgroundCheong, J. K., Hung, N. T., Wang, H., Tan, P., Voorhoeve, P. M., Lee, S. H., & Virshup, D. M. (2011) · Oncogene · doi:10.1038/onc.2010.627 · Cited by 119 · cited 1×
“Not only that, IC261 has alternatively biological effects that may lead to the death of cancer cells independent of inhibiting the canonical Wnt pathway.(352,354) In an in vitro study, IC261 induced centrosome fragmentation during mitosis independent of CK1δ.”
BackgroundProtein Phosphatase 2Cα Dephosphorylates Axin and Activates LEF-1-dependent Transcription
Strovel, E. T., Wu, D., & Sussman, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.4.2399 · Cited by 118 · cited 4×
“DIX, a highly conserved domain, is indispensable for the recognition of Axin.196 Moreover, DIX mediated the polymerization of Dvl monomer, which assembles as the anchoring site for Axin and Gsk3β.197 This process may have significant effects on the ligand–receptor/co-receptor internalization.”
BackgroundInfluentialHan, T., Schatoff, E. M., Murphy, C., Zafra, M. P., Wilkinson, J. E., Elemento, O., & Dow, L. E. (2017) · Nature Communications · doi:10.1038/ncomms15945 · Cited by 118 · cited 1×
“can initiate and maintain tumor development absolutely through Wnt signals.(120) Apart from Rspos, the mutations of Znrf3/Rnf43 were also proposed to participate in CRC.”
BackgroundWang, H., Deng, G., Ai, M., Xu, Z., Mou, T., Yu, J., Liu, H., Wang, S., & Li, G. (2019) · Oncogene · doi:10.1038/s41388-018-0532-5 · Cited by 117 · cited 1×
“Herein, stabilizing of Lrp5 by Hsp90ab1 enhanced gastric cancer progression.(112) Moreover, LRP6 also plays a positive role in various cancers, such as CRC, breast cancer, prostate cancer, and so on.”
BackgroundPre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1
Choi, M. Y., Widhopf, G. F., Wu, C. C. N., Cui, B., Lao, F. S., Sadarangani, A., Cavagnaro, J. A., Prussak, C. E., Carson, D. A., Jamieson, C. H. M., et al. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.02.010 · Cited by 117 · cited 2×
“As normal B lymphocytes do not express ROR1, UC-961 has precise and good effects in treating CLL.(319)”
BackgroundSelf-citationMartins-Neves, S. R., Paiva-Oliveira, D. I., Fontes-Ribeiro, C., Bovée, J. V. M. G., Cleton-Jansen, A.-M., & Gomes, C. M. F. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.004 · Cited by 115 · cited 1×
“IWR-1 served as a good adjuvant that reversed the resistance of osteosarcoma to doxorubicin, and in vivo inhibited the growth of subcutaneous PDX osteosarcoma.(342) Moreover, IWR-1 could inhibit the EMT of CRC by inhibiting Wnt/β-catenin transduction.”
BackgroundGandhirajan, R. K., Staib, P. A., Minke, K., Gehrke, I., Plickert, G., Schlösser, A., Schmitt, E. K., Hallek, M., & Kreuzer, K.-A. (2010) · Neoplasia · doi:10.1593/neo.91972 · Cited by 115
Evidence for the involvement of the Wnt 2 gene in human colorectal cancer.
Vider, B. Z., Zimber, A., Chastre, E., Prevot, S., Gespach, C. P., Estlein, D., Wolloch, Y., Tronick, S. R., Gazit, A., & Yaniv, A. (1996) · PubMed · Cited by 115
Lai, C., Wu, J.-C., Yu, S., Badmaev, V., Nagabhushanam, K., Ho, C., & Pan, M. (2011) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100290 · Cited by 114
Kimura, K., Ikoma, A., Shibakawa, M., Shimoda, S., Harada, K., Saio, M., Imamura, J., Osawa, Y., Kimura, M., Nishikawa, K., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.08.016 · Cited by 112 · cited 1×
“However, they seemed to be more applicable in antifibrosis than in antitumor.(391,392) BCL9 provides an excellent opportunity for targeting Wnt signaling therapy.”
BackgroundPronobis, M. I., Rusan, N. M., & Peifer, M. (2015) · eLife · doi:10.7554/elife.08022 · Cited by 112 · cited 2×
“In Wnt/β-catenin signaling, generally, Gsk3 controls β-catenin degradation by comprising a degradation complex.(95,133,181) Axin, phosphorylated by Gsk3, binds to and phosphorylates β-catenin, resulting in β-catenin degradation by ubiquitin proteasome.”
BackgroundDiederich, M. F. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.905 · Cited by 111
Zhang, W., Yang, J., Liu, Y., Chen, X., Yu, T., Jia, J., & Liu, C. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.013698 · Cited by 110
Kaur, M., Velmurugan, B., Tyagi, A., Agarwal, C., Singh, R. P., & Agarwal, R. (2010) · Neoplasia · doi:10.1593/neo.10188 · Cited by 110
Davis, S. L., Cardin, D. B., Shahda, S., Lenz, H.-J., Dotan, E., O’Neil, B. H., Kapoun, A. M., Stagg, R. J., Berlin, J., Messersmith, W. A., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-019-00824-1 · Cited by 109 · cited 1×
“In detail, in a clinical trial with metastatic pancreatic cancer, two participants experienced fragility fractures at 7 mg/kg q2w.(311) Additionally, in a trial attempted to treat advanced or metastatic HER2 breast cancer, vanticumab led to fragility fractures in 3 patients, including three Grade 2 events and one Grad…”
BackgroundLu, W., & Li, Y. (2014) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24850 · Cited by 109 · cited 2×
“Other old drugs like niclosamide to inhibit canonical Wnt signaling by promoting Fzd1 endocytosis,(404) celecoxib to induce the degradation of Tcf7,(405) and salinomycin to target LRP6.(406) Due to the functions of these old drugs for targeting Wnt/β-catenin signaling are still limitedly known, we will not continue to…”
BackgroundJung, C., Kim, R.-S., Lee, S.-J., Wang, C., & Jeng, M.-H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2614 · Cited by 108 · cited 2×
“Specifically, HOXB13 expression was downregulated in colorectal and prostate cancer.(240,241) And it inhibited the growth of cancers by reducing Tcf and c-myc protein levels.”
BackgroundSelf-citationMechanisms of Wnt signaling and control
Grainger, S. J., & Willert, K. (2018) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1422 · Cited by 108 · cited 1×
“The highly conserved cysteine-rich domain (CRD) of Fzds manipulates the ligand recognition and binding.(15,17) In addition, as co-receptors to Wnt ligands, Lrps consist of Lrp5 and 6, whose extracellular domains interact with Fzds and then its intracellular domains trigger further signaling transduction.”
BackgroundInvolvement of adenomatous polyposis coli (APC)/β-catenin signalling in human breast cancer
Jönsson, M., Borg, Å., Nilbert, M. C., & Andersson, T. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00276-2 · Cited by 107
The Development of Highly Potent Inhibitors for Porcupine
Wang, X., Moon, J., Dodge, M. E., Pan, X., Zhang, L., Hanson, J. M., Tuladhar, R., Ma, Z., Shi, H., Williams, N. S., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400159c · Cited by 106 · cited 1×
“IWP-2 and IWP-L6 had poor metabolic stability in mice, but at least IWPL6 showed relatively better stability in human.(300) IWPs may synergist with PRI-724 to induce apoptosis in HNSCC through inhibition of both Porc and CBP/β-catenin.”
BackgroundLu, D., Liu, J. X., Endo, T., Zhou, H., Yao, S., Willert, K., Schmidt‐Wolf, I. G. H., Kipps, T. J., & Carson, D. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008294 · Cited by 105
Milovanovic, T., Planutis, K., Nguyen, A., Marsh, J., Lin, F., Hope, C., & Holcombe, R. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.5.1337 · Cited by 105
Yuan, H., Mao, J., Li, L., & Wu, D. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.43.30419 · Cited by 104
HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated transactivation
Jung, C., Kim, R.-S., Zhang, H., Lee, S.-J., Sheng, H., Loehrer, P. J., Gardner, T. A., Jeng, M.-H., & Kao, C. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602631 · Cited by 104 · cited 2×
“Specifically, HOXB13 expression was downregulated in colorectal and prostate cancer.(240,241) And it inhibited the growth of cancers by reducing Tcf and c-myc protein levels.”
BackgroundMoore, K. N., Gunderson, C. C., Sabbatini, P., McMeekin, D. S., Mantia-Smaldone, G., Burger, R. A., Morgan, M. A., Kapoun, A. M., Brachmann, R. K., Stagg, R., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.04.001 · Cited by 104 · cited 1×
“Another trial recruited patients inflicted with recurrent ovarian cancer, in which a patient experienced a pelvic fracture at 5 mg/ kg q3w.(310) Studies pointed out that vanticumab had a more severe side effect on bone than ipafricept.”
BackgroundBrennan, K., Gonzalez-Sancho, J. M., Castelo-Soccio, L. A., Howe, L. R., & Brown, A. M. (2004) · Oncogene · doi:10.1038/sj.onc.1207642 · Cited by 103 · cited 1×
“In addition, as co-receptors to Wnt ligands, Lrps consist of Lrp5 and 6, whose extracellular domains interact with Fzds and then its intracellular domains trigger further signaling transduction.(18,19) In addition to receptor/coreceptors, there also exist certain extracellular regulators that can influence the ligand–…”
BackgroundAtkinson, J. M., Rank, K. B., Zeng, Y., Capen, A., Yadav, V., Manro, J. R., Engler, T. A., & Chedid, M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125028 · Cited by 103
Modulating Wnt signaling at the root: Porcupine and Wnt acylation
Torres, V. I., Godoy, J. A., & Inestrosa, N. C. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.009 · Cited by 102 · cited 1×
“Especially, the acylation is necessary for extracellular transport and receptor/co-receptors recognition and bounding.(14,15) With respect to the receptor/co-receptors of Wnt/β-catenin signaling, including frizzled (Fzd) receptors and Lrp”
BackgroundUeno, K., Hirata, H., Majid, S., Yamamura, S., Shahryari, V., Tabatabai, Z. L., Hinoda, Y., & Dahiya, R. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0592 · Cited by 101
Small-molecule binding of the axin RGS domain promotes β-catenin and Ras degradation
Cha, P.-H., Cho, Y.-H., Lee, S.-K., Lee, J., Jeong, W.-J., Moon, B.-S., Yun, J.-H., Yang, J. S., Choi, S., Yoon, J., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2103 · Cited by 101 · cited 2×
“Controlling Axin polymerization may be a potential therapeutic choice to suppress cancer development.(154,155) Mutations of AxinCR were reported to accelerate the tumorigenesis in the following cancers: HCC, colorectal adenomas, ovarian carcinomas, lung carcinomas, and sporadic medulloblastomas.”
BackgroundMa, L., Wang, X., Jia, T., Wei, W., Chua, M.-S., & So, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4455 · Cited by 100
Shrivastava, S., Jeengar, M. K., Thummuri, D., Koval, A., Katanaev, V. L., Marepally, S. K., & Naidu, V. G. M. (2016) · BioFactors · doi:10.1002/biof.1315 · Cited by 100
Bone loss from Wnt inhibition mitigated by concurrent alendronate therapy
Madan, B., McDonald, M. J., Foxa, G. E., Diegel, C. R., Williams, B. O., & Virshup, D. M. (2018) · Bone Research · doi:10.1038/s41413-018-0017-8 · Cited by 99 · cited 4×
“Results showed that there were no significant differences in several estimated outcomes of bone between treated daily and treated every other day.(280) By the way, ETC131, a similar compound of ETC159, is only used for in vitro assays as a result of its inferior oral bioavailability.”
BackgroundInfluentialXIAP Monoubiquitylates Groucho/TLE to Promote Canonical Wnt Signaling
Hanson, A. J., Wallace, H. A., Freeman, T. J., Beauchamp, R. D., Lee, L. A., & Lee, E. N. (2012) · Molecular Cell · doi:10.1016/j.molcel.2011.12.032 · Cited by 99 · cited 2×
“Tcf binds to Groucho/TLE, CtBP, and histone deacetylase proteins when β-catenin signaling is not activated.217–219 Tcf/Lef separates from Groucho/TLE and then composites β-catenin–Lef/Tcf complex, depending on X-linked inhibitor of apoptosis (XIAP) monoubiquitylating Groucho (Gro)/ TLE.220 CBP promotes the transactiva…”
BackgroundCapsaicin represses transcriptional activity of β-catenin in human colorectal cancer cells
Lee, S., Richardson, R. L., Dashwood, R. H., & Baek, S. J. (2011) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.03.009 · Cited by 99
Wechter, W. J., Kantoci, D., Murray, E. D., Quiggle, D. D., Leipold, D. D., Gibson, K. M., & McCracken, J. D. (1997) · PubMed · Cited by 98
Gazit, A., Yaniv, A., Bafico, A., Tata, P., Igarashi, M., Kitajewski, J., & Aaronson, S. A. (1999) · Oncogene · doi:10.1038/sj.onc.1202985 · Cited by 98
Fiskus, W., Sharma, S., Saha, S., Shah, B., Devaraj, S. G. T., Sun, B., Horrigan, S., Leveque, C., Zu, Y., Iyer, S., et al. (2015) · Leukemia · doi:10.1038/leu.2014.340 · Cited by 98 · cited 1×
“Moreover, BC2059, an anthraquinone oxime-analog repressing Lef1/Tcf4 activity, was elucidated to induce the apoptosis of HL-60, HEL, and K562 significantly.(384,385) BC2059 is currently testified in a phase I clinical trial of desmoid tumor (Table 2).”
BackgroundEndo, Y., Beauchamp, E., Woods, D., Taylor, W. G., Toretsky, J. A., üren, A., & Rubin, J. S. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01780-07 · Cited by 97
Small-molecule modulation of Wnt signaling via modulating the Axin-LRP5/6 interaction
Wang, S., Yin, J., Chen, D., Nie, F., Song, X., Fei, C., Miao, H., Jing, C., Ma, W., Wang, L., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1309 · Cited by 96 · cited 2×
“An SMI from the synthetic chemical library of lycorine derivatives, 4-ethyl-5-methyl-5,6dihydro-[1,3]dioxolo[4,5-j]phenanthridine (HLY78), activated Wnt/ β-catenin signaling by targeting the DIX domain of Axin and enhanced the effect of Axin-Lrp5/6.(351)”
BackgroundInfluentialCaveolin-1–LRP6 Signaling Module Stimulates Aerobic Glycolysis in Prostate Cancer
Tahir, S. A., Yang, G., Goltsov, A. A., Song, K., Ren, C., Wang, J., Chang, W., & Thompson, T. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3040 · Cited by 95
Wnt3a stimulation elicits G-protein-coupled receptor properties of mammalian Frizzled proteins
Koval, A., & Katanaev, V. L. (2011) · Biochemical Journal · doi:10.1042/bj20101878 · Cited by 93
APC mutations are infrequent but present in human lung cancer
Ohgaki, H. (2003) · Cancer Letters · doi:10.1016/j.canlet.2003.10.020 · Cited by 93
Allele loss from 5q21 (APC/MCC) and 18q21 (DCC) and DCC mRNA expression in breast cancer
Thompson, A., Morris, R., Wallace, M., Wyllie, A. H., Steel, C. M., & Carter, D. C. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.287 · Cited by 90
Therapeutic targets in the Wnt signaling pathway: Feasibility of targeting TNIK in colorectal cancer
Masuda, M., Sawa, M., & Yamada, T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.10.009 · Cited by 89 · cited 2×
“N5355 significantly reduced the expression of Wnt/β-catenindependent genes, such as Axin2 and cMYC, in HCT-116 cell line.(373) What’s worth noting, N5355 did not affect the vitality of canonical Wnt signaling independent cell lines, HELA and HEL299.”
BackgroundLi, Y., Lü, W., He, X., Schwartz, A. L., & Bu, G. (2004) · Oncogene · doi:10.1038/sj.onc.1208123 · Cited by 89
Corda, G., Sala, G., Lattanzio, R., Iezzi, M., Sallese, M., Fragassi, G., Lamolinara, A., Mirza, H., Barcaroli, D., Ermler, S., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4841 · Cited by 88
PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers
Zhong, Z., Sepramaniam, S., Chew, X. H., Wood, K., Lee, M. A., Madan, B., & Virshup, D. M. (2019) · Oncogene · doi:10.1038/s41388-019-0908-1 · Cited by 87 · cited 2×
“ETC159 can perform effectively synergistic effects with PI3k/mTor inhibitor GDC-0941 in PDAC with Rnf43 LoF mutation.(278) Based on the outstanding behavior of ETC159 in a preclinical experiment, another phase II clinical trial targeting advanced solid tumors has been carried out.”
Backgroundde Groot, R. E. A., Ganji, R. S., Bernatík, O., Lloyd‐Lewis, B., Seipel, K., Šedová, K., Zdráhal, Z., Dhople, V. M., Dale, T. C., Korswagen, H. C., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2004985 · Cited by 86 · cited 2×
“CK1ε phosphorylating mediated DIX-E3 ligase interaction ubiquitinates Dvl, abolishing the polymerization of Dvls, ultimately inhibiting Wnt/β-catenin signaling.(192) Next, the PDZ domain lying in the central part of Dvls, essential for the signal conduct from Fzd to downstream molecules, is also the most druggable reg…”
BackgroundMahmoudi, T., Boj, S. F., Hatzis, P., Li, V. S. W., Taouatas, N., Vries, R. G. J., Teunissen, H., Begthel, H., Korving, J., Mohammed, S., et al. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000539 · Cited by 86
Shetti, D., Zhang, B., Fan, C., Mo, C., Lee, B. H., & Wei, K. (2019) · Cells · doi:10.3390/cells8080892 · Cited by 85 · cited 1×
“This mechanism was contributed to inhibiting Wnt/ β-catenin signaling to enhance cancer cell apoptosis and attenuate EMT and angiogenesis.(330) In gastric cancer, XAV939 can inhibit the invasion and metastasis of cancer cells.”
BackgroundmiR-19 targeting of GSK3β mediates sulforaphane suppression of lung cancer stem cells
Zhu, J., Wang, S., Chen, Y., Li, X., Jiang, Y., Yang, X., Li, Y., Wang, X., Meng, Y., Zhu, M., et al. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.02.020 · Cited by 85
Camps, J., Pitt, J. J., Emons, G., Hummon, A. B., Case, C. M., Grade, M., Jones, T. L., Nguyen, Q. T., Ghadimi, B. M., Beissbarth, T., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3159 · Cited by 85 · cited 13×
“The constitutive activation form of β-catenin, the exon 3 mutations, is believed to regulate the Signal Transduction and Targeted Therapy (2021) 6:307 genesis of hereditary non-polyposis CRC.208 In CRC, there are several mutations of β-catenin, leading to abnormally activated Wnt/β-catenin signaling.209 The mutations…”
BackgroundInfluential3BP2-deficient mice are osteoporotic with impaired osteoblast and osteoclast functions
Levaot, N., Simoncic, P. D., Dimitriou, I. D., Scotter, A. J., Rose, J. L., Ng, A., Willett, T. L., Wang, C. J., Janmohamed, S., Grynpas, M. D., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45843 · Cited by 84
Self-citationCompartment switching of WNT-2 expression in human breast tumors.
Dale, T. C., Weber-Hall, S. J., Smith, K., Huguet, E., Jayatilake, H., Gusterson, B. A., Shuttleworth, G., O'Hare, M. J., & Harris, A. L. (1996) · PubMed · Cited by 83
Minke, K. S., Staib, P., Puetter, A., Gehrke, I., Gandhirajan, R. K., Schlösser, A., Schmitt, E. K., Hallek, M., & Kreuzer, K. (2009) · European Journal of Haematology · doi:10.1111/j.1600-0609.2008.01188.x · Cited by 82
Rizzieri, D. A., Cooley, S., Odenike, O., Moonan, L., Chow, K. H., Jackson, K., Wang, X., Brail, L., & Borthakur, G. (2016) · Leukemia & Lymphoma · doi:10.3109/10428194.2015.1122781 · Cited by 81 · cited 1×
“GSK3/inhibitor LY2090314 NCT01214603(440) (P2); NCT01287520(441) (P1); Rizzieri et al.(442); Gray et al.”
Evidence for tankyrases as antineoplastic targets in lung cancer
Busch, A. M., Johnson, K. C., Stan, R. V., Sanglikar, A., Ahmed, Y., Dmitrovsky, E., & Freemantle, S. J. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-211 · Cited by 81
APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer
Tanaka, N., Mashima, T., Mizutani, A., Sato, A., Aoyama, A., Gong, B., Yoshida, H., Muramatsu, Y., Nakata, K., Matsuura, M., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0578 · Cited by 81 · cited 1×
“These results suggested an underlying therapeutic value of Tnks for dealing with truncated Apc mutant cancers.(329) XAV939 was identified as an inhibitory factor of Wnt/β-catenin signaling, originally in CRC cell lines.”
BackgroundGray, J. E., Infante, J. R., Brail, L. H., Simon, G. R., Cooksey, J. F., Jones, S. F., Farrington, D. L., Yeo, A. S. L., Jackson, K. A., Chow, K. H., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0278-7 · Cited by 81
Mizutani, A., Yashiroda, Y., Muramatsu, Y., Yoshida, H., Chikada, T., Tsumura, T., Okue, M., Shirai, F., Fukami, T., Yoshida, M., et al. (2018) · Cancer Science · doi:10.1111/cas.13805 · Cited by 80 · cited 1×
“It could down-regulate the Wnt/β-catenin signaling in Apc-truncated CRC cells, but had little effects in wild-type cancer cells.(350) An SMI from the synthetic chemical library of lycorine derivatives, 4-ethyl-5-methyl-5,6dihydro-[1,3]dioxolo[4,5-j]phenanthridine (HLY78), activated Wnt/ β-catenin signaling by targetin…”
BackgroundCanesin, G., Axelsson, S. E., Hellsten, R., Krzyzanowska, A., Prasad, C. P., Bjartell, A. S., & Andersson, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184418 · Cited by 80 · cited 1×
“In accordance, foxy-5 could prevent metastasis to some extent.(321,322) At present, WntResearch has supported five clinical trials registered on NIH and EUCTR, yet with no results posted (Table 2).”
BackgroundHIF-2α Enhances β-Catenin/TCF-Driven Transcription by Interacting with β-Catenin
Choi, H., Chun, Y.-S., Kim, T.-Y., & Park, J.-W. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0505 · Cited by 79 · cited 1×
“Accordingly, utilizing Tanshinone IIA can inhibit CRC angiogenesis by means of interrupting HIF-1α/β-catenin/Tcf3/ Lef1 signaling.(238,239) Besides, HOXB13, SOX4, RUNX3, CDK8, TCTP, and Daxx participate in regulating Wnt/β-catenin signaling to target Tcf in numerous cancers.”
MethodAhn, Y., Sims, C., Logue, J. M., Weatherbee, S. D., & Krumlauf, R. (2013) · Development · doi:10.1242/dev.085118 · Cited by 79
Björklund, P., Åkerström, G., & Westin, G. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040328 · Cited by 78 · cited 1×
“Generally, the truncated LRP5 amplified Wnt/β-catenin signaling to severely promote the growth of parathyroid tumors.(111) Herein, stabilizing of Lrp5 by Hsp90ab1 enhanced gastric cancer progression.”
BackgroundHansen, C., Howlin, J., Tengholm, A., Dyachok, O., Vogel, W. F., Nairn, A. C., Greengard, P., & Andersson, T. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.048884 · Cited by 78
WNT-1 inducible signaling pathway protein-1 enhances growth and tumorigenesis in human breast cancer
Chiang, K.-C., Yeh, C.-N., Chung, L.-C., Feng, T.-H., Sun, C.-C., Chen, M.-F., Jan, Y.-Y., Yeh, T.-S., Chen, S.-C., & Juang, H.-H. (2015) · Scientific Reports · doi:10.1038/srep08686 · Cited by 77 · cited 1×
“Nevertheless, a Wnt1-dependent gene, Wnt1-inducible signaling pathway protein 2 (WISP2), was reported to effectively undermine the immunologic evasion of cancer cells.(39,44) In addition to the direct involvements of Wnt1 in cancers, certain upstream modulators of Wnt1 can repress the viability of a few sorts of cance…”
BackgroundLee, M. A., Park, J.-H., Rhyu, S. Y., Oh, S.-T., Kang, W.-K., & Kim, H.-N. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-125 · Cited by 77
The β-catenin/YAP signaling axis is a key regulator of melanoma-associated fibroblasts
Liu, T., Zhou, L., YANG, K. Y., Iwasawa, K., Kadekaro, A. L., Takebe, T., Andl, T., & Zhang, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0100-7 · Cited by 76 · cited 1×
“In addition, the transcription complex recruits p300/CBP,(222,223) Bcl9,(224) Pontin522,(225) Reptin52,(225) Brg-1,(226,227) Mllt/Af10-Dot1,(228) SOX10,(229) p68/p72,(230) βTrCp1/Fbw1a,(231) FOXM1, and yes-associated protein 1 (YAP1).(235,236) However, in CRC, HIFα can competitively bound to β-catenin to abolish the T…”
BackgroundKim, J.-Y., Lee, H.-Y., Park, K.-K., Choi, Y.-K., Nam, J.-S., & Hong, I.-S. (2016) · Oncotarget · doi:10.18632/oncotarget.7954 · Cited by 74 · cited 2×
“CWP232228 is such an inhibitor, which was reported to induce apoptosis and cell cycle arrest in HCT116 cells,(380) also to show effects on liver and breast CSCs.(381,382) LF3, a 4-thioureido-benzenesulfonamide derivative, reduced tumor growth and induced differentiation in a CRC xenograft murine model.”
BackgroundHu, P., Ke, C., Guo, X., Ren, P., Tong, Y., Luo, S., He, Y., Wei, Z., Cheng, B., Li, R., et al. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.06.012 · Cited by 74
Williams, S. P., Nowicki, M. O., Liu, F., Press, R., Godlewski, J., Abdel-Rasoul, M., Kaur, B., Fernandez, S. A., Chiocca, E. A., & Lawler, S. E. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3026 · Cited by 74
Kleeman, S. O., Koelzer, V. H., Jones, H. J., Vazquez, E. G., Davis, H., East, J. E., Arnold, R., Koppens, M. A., Blake, A., Domingo, E., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-319126 · Cited by 73 · cited 3×
“For instance, the R-spondins (Rspo), member 1/2/3/4,20 which coordinates with leucine-rich repeat-containing GPCR (Lgr) 4/ 5/6 to enhance Wnt/β-catenin signaling.21–24 Specifically, the Rspo-Lgr complex increases Lrp5/6 phosphorylation and inactivates Wnt repressors Rnf43 and Znrf3.”
BackgroundEgashira, I., Takahashi‐Yanaga, F., Nishida, R., Arioka, M., Igawa, K., Tomooka, K., Nakatsu, Y., Tsuzuki, T., Nakabeppu, Y., Kitazono, T., et al. (2016) · Cancer Science · doi:10.1111/cas.13106 · Cited by 73
Pavlovic, Z., Adams, J., Blazer, L. L., Gakhal, A. K., Jarvik, N., Steinhart, Z., Robitaille, M., Mascall, K. S., Pan, J., Angers, S., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1515565 · Cited by 73 · cited 3×
“They are characterized by high affinity and low off-target accidents but have longer plasma half-life and lessened clearance rate.305 OMP-18R5/OMP-54F28.”
BackgroundInfluentialConditional Disruption of Axin1 Leads to Development of Liver Tumors in Mice
Feng, G. J., Cotta, W., Wei, X., Poetz, O., Evans, R., Jardé, T., Reed, K. R., Méniel, V. S., Williams, G. T., Clarke, A. R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.08.047 · Cited by 73 · cited 2×
“This mutation could phenocopy various tumors in animal models.(158,159) Axin2 can partially compensate for the functional impairment caused by Axin1 mutation.”
BackgroundTargeting the Wnt signaling pathway in colorectal cancer
Sawa, M., Masuda, M., & Yamada, T. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1098619 · Cited by 73 · cited 4×
“What’s worth noting, N5355 did not affect the vitality of canonical Wnt signaling independent cell lines, HELA and HEL299.(252) This research group subsequently discovered NCB0005 (or called KY-05009), which markedly inhibited the activation of Wnt/β-catenin signaling mediated by TGF-β1 in A549 cells.”
BackgroundInfluentialMolecular cloning and characterization of human WNT3
Katoh, M. (2001) · International Journal of Oncology · doi:10.3892/ijo.19.5.977 · Cited by 73 · cited 3×
“Studies indicated that R2 and B motifs of Apc were the binding sites of Apc-Gsk3β/Axin, by which complex the diversity and structural stability of Axin were promoted.(60) The loss-of-function (LoF) of Apc may be an essential contributor to various cancers, especially CRC.”
BackgroundInfluentialStructure–Function analysis of secreted frizzled‐related protein‐1 for its Wnt antagonist function
Bhat, R. A., Stauffer, B., Komm, B. S., & Bodine, P. V. N. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21372 · Cited by 72
Lü, W., Lin, C., & Li, Y. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.02.018 · Cited by 72
Akalay, I., Tan, T. Z., Kumar, P., Janji, B., Mami‐Chouaib, F., Charpy, C., Vielh, P. R., Larsen, A. K., Thiery, J. P., Sabbah, M., et al. (2014) · Oncogene · doi:10.1038/onc.2014.151 · Cited by 71 · cited 1×
“Nevertheless, a Wnt1-dependent gene, Wnt1-inducible signaling pathway protein 2 (WISP2), was reported to effectively undermine the immunologic evasion of cancer cells.(39,44) In addition to the direct involvements of Wnt1 in cancers, certain upstream modulators of Wnt1 can repress the viability of a few sorts of cance…”
BackgroundHSP105 Recruits Protein Phosphatase 2A To Dephosphorylate β-Catenin
Yu, N., Kakunda, M., Pham, V. C., Lill, J. R., Du, P., Wongchenko, M. J., Yan, Y., Firestein, R., & Huang, X. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.01307-14 · Cited by 71 · cited 1×
“Hsp105, a PP2A regulator, is overexpressed in various tumors to reduce β-catenin degradation.(206) Researches showed that PP2A dephosphorylated β-catenin to increase β-catenin accumulation.”
BackgroundCurcumin inhibits the growth via Wnt/β-catenin pathway in non-small-cell lung cancer cells.
Wang, J.-Y., Wang, X., Wang, X.-J., Bz, Z., Wang, Y., Wang, X., & Liang, B. (2018) · PubMed · doi:10.26355/eurrev_201811_16290 · Cited by 71
Self-citationZhang, C., Zhang, Z., Zhang, S., Wang, W., & Hu, P. (2017) · Medical Science Monitor · doi:10.12659/msm.901667 · Cited by 70
Kulak, O., Chen, H., Holohan, B., Wu, X., He, H., Borek, D., Otwinowski, Z., Yamaguchi, K., Garofalo, L. A., Ma, Z., et al. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00392-15 · Cited by 70 · cited 1×
“IWRs, including five molecules, target Wnt-dependent cancers by enhancing Axin capability to suppress Wnt/β-catenin signaling.(299,341) The inhibition of IWRs has been identified in various cancers like osteosarcoma, colorectal, breast, lung, and hepatocellular cancers.”
BackgroundWnt signaling dynamics in head and neck squamous cell cancer tumor‐stroma interactions
Le, P. N., Keysar, S. B., Miller, B., Eagles, J. R., Chimed, T., Reisinger, J., Gomez, K. E., Nieto, C., Jackson, B. C., Somerset, H. L., et al. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.22937 · Cited by 70 · cited 1×
“Aberrant Wnt/β-catenin signaling has been uncovered to be tightly woven with many aspects of cancers, including the onset, progression, malignant transformation, and so on.(2,3) Evidence-based medicine has further proved that the abnormal activation of this signaling showed nonnegligible effects on cancer-associated m…”
BackgroundGu, X., Yao, L., Ma, G., Cui, L., Li, Y., Liang, W., Zhao, B., & Li, K. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not194 · Cited by 70 · cited 1×
“The translationally controlled tumor protein (TCTP) can enhance the transcription complex activity by increasing the ability of β-catenin–Tcf binding and then inducing the growth of glioma tumor.(247) In summary, HOXB13 and RUNX3 are identified as suppressors of Wnt/β-catenin signaling by obstructing Tcf4 activity to…”
BackgroundSelf-citationCheng, Y., Phoon, Y. P., Jin, X. A., Chong, S. Y. S., Ip, J. C. Y., Wong, B. W. Y., & Lung, M. L. (2015) · Oncotarget · doi:10.18632/oncotarget.3982 · Cited by 69 · cited 1×
“And WNT-C59 satisfactorily prevented tumor growth in mice xenografted with SUNE1 or HNE1 (two nasopharyngeal carcinoma cell lines).(296) In addition, WNT-C59 can reverse the resistance of trichostatin A in human pancreatic cells.”
BackgroundThe utility of Apc-mutant rats in modeling human colon cancer
Irving, A. A., Yoshimi, K., Hart, M. L., Parker, T. W., Clipson, L. J., Ford, M. R., Kuramoto, T., Dove, W. F., & Amos-Landgraf, J. M. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.016980 · Cited by 69 · cited 1×
“Traf2- and Nck-interacting kinase (Tnik) is one member of germinal center kinases (GCKs) that can activate the c-Jun Nterminal kinase pathway.(139) Tnik is an essential component for Wnt/β-catenin signaling to maintain physiological cell homeostasis.”
BackgroundMizushima, T., Nakagawa, H., Kamberov, Y. G., Wilder, E. L., Klein, P. S., & Rustgi, A. K. (2002) · PubMed · Cited by 69
Pak, S., Park, S., Kim, Y., Park, J., Park, C. H., Lee, K.-J., Kim, C., & Ahn, H. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1342-5 · Cited by 68 · cited 1×
“CWP291 was reported to suppress the growth of castration-resistant prostate cancer through the degradation of β-catenin via apoptosisinduced ER stress.(323) In fact, CWP232204 is the active form of CWP291 in serum.”
BackgroundWei, Q., Zhao, Y., Yang, Z., Dong, Q., Dong, X.-J., Han, Y., Chen, Z., & Wang, E. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.06.018 · Cited by 67 · cited 1×
“peripheral blood mononuclear cells, Dvl1-3 were found to be exclusively expressed in NSCLC and CLL cells, respectively.(368,369) Most drugs targeting Dvls currently are developed to selectively inhibit PDZ-Fzd interaction.”
BackgroundAnti-LRP5/6 VHHs promote differentiation of Wnt-hypersensitive intestinal stem cells
Fenderico, N., van Scherpenzeel, R. C., Goldflam, M., Proverbio, D., Jordens, I., Kralj, T., Stryeck, S., Bass, T. Z., Hermans, G., Ullman, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08172-z · Cited by 67 · cited 1×
“The single-domain antibody fragments of Lrp5/6 can effectively relieve the development of intestinal cancers.(110) Generally, the truncated LRP5 amplified Wnt/β-catenin signaling to severely promote the growth of parathyroid tumors.”
BackgroundStakheev, D., Táborská, P., Strizova, Z. O., Podrazil, M., Bartůňková, J., & Smrž, D. (2019) · Scientific Reports · doi:10.1038/s41598-019-41182-5 · Cited by 67 · cited 2×
“XAV939 enhanced the ability of CD4 lymphocytes in biochemically recurrent prostate cancer cell lines, LNCaP and PC-3.(335) JW67 and JW74, two compounds as inhibitory molecules of Wnt/β-catenin signaling, can inhibit the growth of CRC by Axin2 accumulation and β-catenin degradation.”
BackgroundThe FOXM1 Inhibitor RCM-1 Decreases Carcinogenesis and Nuclear β-Catenin
Shukla, S., Milewski, D., Pradhan, A., Rama, N., Rice, K., Le, T. T., Flick, M. J., Vaz, S., Zhao, X., Setchell, K. D. R., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0709 · Cited by 66
Wnt pathway activation by ADP-ribosylation
Yang, E., Tacchelly-Benites, O., Wang, Z., Randall, M. P., Tian, A., Benchabane, H., Freemantle, S., Pikielny, C., Tolwinski, N. S., Lee, E., et al. (2016) · Nature Communications · doi:10.1038/ncomms11430 · Cited by 66 · cited 1×
“Additionally, researches showed that tankyrase enhanced Wnt/β-catenin signaling.(176,177) A series of studies further proved that tankyrase could suppress cancer development via inhibiting the Wnt/β-catenin signaling pathway.”
BackgroundBaruah, M. M., Khandwekar, A. P., & Sharma, N. (2016) · Tumor Biology · doi:10.1007/s13277-016-5277-6 · Cited by 66
Picco, G., Petti, C., Centonze, A., Torchiaro, E., Crisafulli, G., Novara, L., Acquaviva, A., Bardelli, A., & Medico, E. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606773 · Cited by 64 · cited 3×
“This kind of drug resistance is accomplished by LoF of Axin1 in the VACO6.”
Intranasal wnt3a Attenuates Neuronal Apoptosis through Frz1/PIWIL1a/FOXM1 Pathway in MCAO Rats
Matei, N., Camara, J. R., McBride, D. W., Câmara, R., Xu, N., Tang, J., & Zhang, J. H. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.2352-17.2018 · Cited by 64
Liu, Z., Sun, L., Cai, Y., Shen, S., Zhang, T., Wang, N., Wu, G., Ma, W., Li, S.-T., Suo, C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2876 · Cited by 63
Giraudet, A.-L., Cassier, P. A., Iwao-Fukukawa, C., Garin, G., Badel, J.-N., Kryza, D., Chabaud, S., Gilles-Afchain, L., Clapisson, G., Desuzinges, C., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4544-x · Cited by 63 · cited 1×
“Furthermore, (90)Y-OTSA-101 showed obvious bone marrow suppression and significant hematotoxicity.(320)”
BackgroundOgasawara, N., Tsukamoto, T., Mizoshita, T., Inada, K., Cao, X., Takenaka, Y., Joh, T., & Tatematsu, M. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02560.x · Cited by 63
Huang, C., Chen, Y., Liu, H., Yang, J., Song, X., Zhao, J., He, N., Zhou, C. J., Wang, Y., Huang, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23250 · Cited by 63
Self-citationMo, M., Li, M.-R., Zhao, C., Liu, X.-W., Sheng, Q., & Hai‐Meng, Z. H. O. U. (2013) · Oncology Letters · doi:10.3892/ol.2013.1256 · Cited by 63 · cited 1×
“The growth of gastric cancer cells was restrained via the IWPs-mediated downregulation of Wnt/β-catenin signaling.(304) A similar situation occurred in HNSCC cells as well.”
BackgroundSaha, S. K., Yin, Y., Chae, H. S., & Cho, S. (2019) · Cancers · doi:10.3390/cancers11010099 · Cited by 63
Absorption of pyrvinium pamoate
Smith, T. C., Kinkei, A. W., Gryczko, C. M., & Goulet, J. R. (1976) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1976196802 · Cited by 62 · cited 1×
“Although pyrvinium also showed inhibitory ability in other Wnt/β-catenin signaling-driven tumor cell lines (SUM-149/SUM-159,(358) and A2278(359)), its bioavailability was low in tissues other than the intestine.(360) In addition, pyrvinium also stimulated CK1γ, leading to Wnt signaling suppression.”
BackgroundGarcía-Reyes, B., Witt, L., Jansen, B., Karasu, E., Gehring, T., Leban, J., Henne-Bruns, D., Pichlo, C., Brunstein, E., Baumann, U., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00095 · Cited by 62
Resveratrol targeting the Wnt signaling pathway: A focus on therapeutic activities
Ashrafizadeh, M., Ahmadi, Z., Farkhondeh, T., & Samarghandian, S. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29327 · Cited by 62
Sulindac suppresses β-catenin expression in human cancer cells
Han, A., Song, Z., Tong, C., Hu, D. G., Bi, X., Augenlicht, L. H., & Yang, W. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.12.034 · Cited by 61
Debies, M. T., Gestl, S. A., Mathers, J. L., Mikse, O. R., Leonard, T. L., Moody, S. E., Chodosh, L. A., Cardiff, R. D., & Gunther, E. J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33320 · Cited by 61 · cited 1×
“Conversely, overexpression of Wnt1 promoted the growth of cancers.(48,49) Therapeutically, Blocking Wnt1 has been found to strengthen the apoptosis of colorectal cancer (CRC) cells via the utilization of Wif1, Wnt1-specific siRNAs, and neutralizing antibodies.”
BackgroundSaegusa, M., Hashimura, M., & Kuwata, T. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2011.196 · Cited by 61 · cited 2×
“Specifically, HOXB13 expression was downregulated in colorectal and prostate cancer.240,241 And it inhibited the growth of cancers by reducing Tcf and c-myc protein levels.240,241 RUNX3 inhibited Wnt/β-catenin signaling by comprising of a ternary complex with β-catenin–Tcf and attenuates growth and progression of mult…”
BackgroundInhibition of wnt/β-catenin Signaling in Hepatocellular Carcinoma by an Antipsychotic Drug Pimozide
Fako, V., Yu, Z., Henrich, C. J., Ransom, T., Budhu, A. S., & Wang, X. W. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.14718 · Cited by 61
Nakashima, T., Liu, D., Nakano, J., Ishikawa, S., Yokomise, H., Ueno, M., Kadota, K., & Huang, C. (2008) · Oncology Reports · doi:10.3892/or.19.1.203 · Cited by 61 · cited 1×
“Abnormal Wnt1 expressing patients comprised the majority of cancer patients of non-small cell lung cancer (NSCLC).(43) Nevertheless, a Wnt1-dependent gene, Wnt1-inducible signaling pathway protein 2 (WISP2), was reported to effectively undermine the immunologic evasion of cancer cells.”
BackgroundNovel Binding Mode of a Potent and Selective Tankyrase Inhibitor
Günaydin, H., Gu, Y., & Huang, X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033740 · Cited by 60 · cited 1×
“For the adenosine domain, it is unique to Tnks, and many Tnks inhibitors (G007-LK, NVP-Tnks656, JW55/74, and IWR) target this site.(324) Having been developed for a long time, Tnks inhibitors have shown outstanding tumor-suppressive effects in preclinical experiments, but none of them have entered into clinical trials.”
BackgroundLv, J., Feng, Z., Chen, F., Liu, C., Li, J., Liu, P., Yang, C., Hou, F., & Deng, Z. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23268 · Cited by 60
The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer
Wall, J., Klempner, S. J., & Arend, R. C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1769065 · Cited by 59 · cited 1×
“Though the specific mechanisms are unknown, it was hypothesized that Dkk1 helped tumors escape from immune supervision.(316) Indeed, it was reported that an intact immune system was needed for DKN-01 function in a murine model.”
BackgroundScarborough, H. A., Helfrich, B. A., Casás‐Selves, M., Schuller, A. G., Grosskurth, S. E., Kim, J., Tan, A. C., Chan, D. C. F., Zhang, Z., Zaberezhnyy, V., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1179 · Cited by 59 · cited 2×
“EGFR-driven NSCLC was suppressed by the synergistic function of AZ1366 and EGFR inhibitors.(348) AZ1366 could erase the insensitivity of CRC cells to irinotecan,(349) and it coordinated with EGFR inhibitor to control the growth of Wnt-responsive lung cancers in the murine models.”
BackgroundJanovská, P., Poppová, L., Plevová, K., Plešingerová, H., Běhal, M., Kaucká, M., Ovesná, P., Hložková, M., Borský, M., Stehlíková, O., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0154 · Cited by 59 · cited 1×
“The non-canonical Wnt pathway has been demonstrated to play an important role in CLL with CK1δ/ε overexpression.(356) TGR-1202 is exclusively used in hematological malignancies and is currently recruited in clinical trials for treating CLL, Hodgkin’s lymphoma, mantle cell lymphoma, and so on (Table 2).”
BackgroundCritical Scaffolding Regions of the Tumor Suppressor Axin1 Are Natively Unfolded
Noutsou, M., Duarte, A. M. S., Anvarian, Z., Didenko, T., Minde, D. P., Kuper, I., de Ridder, I., Oikonomou, C., Friedler, A., Boelens, R., et al. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.11.013 · Cited by 58 · cited 2×
“The DIX domain directly affects Dsh protein,(149,151) and AxinCR binds to β-catenin and Gsk3β to regulate Wnt/β-catenin signaling.(33,149,152) Some researches indicated that a single point mutation of Axin destroyed the stabilization of the RGS domain, resulting in Axin polymerization.”
BackgroundMcKie, A. B., Lemoine, N. R., & Filipe, M. I. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550414 · Cited by 58
Insights into Frizzled evolution and new perspectives
Schenkelaars, Q., Fierro‐Constaín, L., Renard, E., Hill, A., & Borchiellini, C. (2015) · Evolution & Development · doi:10.1111/ede.12115 · Cited by 57 · cited 2×
“Fzds, a subset of seven-transmembrane protein, are the principal receptors of canonical Wnt ligands.(80) Fzds, mainly including subfamilies Fzd1/2/7, Fzd3/6, Fzd4, Fzd5/8, and Fzd9/ 10, are ubiquitously expressed in most animal species but not in plants and single-cell eukaryotes.”
BackgroundLee, S. C., Kim, O., Lee, S. K., & Kim, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4354 · Cited by 57 · cited 1×
“Moreover, IWR-1 could inhibit the EMT of CRC by inhibiting Wnt/β-catenin transduction.(343) In the following part, we are going to discuss several agents, NVP-TNKS656, AZ1366, RK-287107, and HLY78, that are Tnks inhibitors with very limited preclinical reports.”
BackgroundGoyal, L., Sirard, C. A., Schrag, M. L., Kagey, M. H., Eads, J. R., Stein, S., El-Khoueiry, A. B., Manji, G. A., Abrams, T. A., Khorana, A. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1310 · Cited by 57 · cited 1×
“Dkk1/mAb DKN-01 NCT03645980(318) (P1/2); NCT01711671(428) (P1); NCT01457417(429) (P1); Goyal et al.(430) EUCTR2018-00413813-GB (P2); NCT04057365(431) (P2); NCT03645980(432) (P1/2) HCC, esophagealgastric cancer, MM, NSCLC, biliary tract cancer”
Wnt3 gene expression promotes tumor progression in non-small cell lung cancer
Nakashima, N., Liu, D., Huang, C., Ueno, M., Zhang, X., & Yokomise, H. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.10.007 · Cited by 57 · cited 1×
“knockdown of Wnt3 could increase drug sensitivity.(64,65) In prostate cancer, inhibiting Wnt3 signaling by the deficiency of trophinin-associated protein attenuated the cancer growth.”
BackgroundAPC gene hypermethylation and prostate cancer: a systematic review and meta-analysis
Chen, Y., Li, J., Yu, X., Li, S., Zhang, X., Mo, Z., & Hu, Y. (2013) · European Journal of Human Genetics · doi:10.1038/ejhg.2012.281 · Cited by 57 · cited 1×
“The DNA methylation of Apc promoter is closely associated with various cancers, like lung cancer and prostatic cancer.(145,146) The methylation reduces the normal expression of Apc in cancers, resulting in abnormal activation of the Wnt/β-catenin signaling pathway.”
BackgroundWnt blockers inhibit the proliferation of lung cancer stem cells
Han, B., Zhang, X., Lou, Y., Zheng, X., Wang, H., Su, J., & Dong, Q. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s76602 · Cited by 57
Kim, H. J., Park, S. Y., Park, O. J., & Kim, Y. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1497 · Cited by 56
Gowrikumar, S., Ahmad, R., Uppada, S. B., Washington, M. K., Shi, C., Singh, A. B., & Dhawan, P. (2019) · Oncogene · doi:10.1038/s41388-019-0795-5 · Cited by 56
Qiao, Y., Wang, J., Karagoz, E., Liang, B., Song, X., Shang, R., Evert, K., Xu, M., Che, L., Evert, M., et al. (2019) · Hepatology · doi:10.1002/hep.30556 · Cited by 55 · cited 1×
“This mutation could phenocopy various tumors in animal models.(158,159) Axin2 can partially compensate for the functional impairment caused by Axin1 mutation.”
BackgroundThe use of porcupine inhibitors to target Wnt-driven cancers
Ho, S. Y., & Keller, T. H. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.10.032 · Cited by 55 · cited 2×
“Mutations of Rnf43, resulting in E3 ubiquitin ligases function loss, promoted CRC development and poor prognosis.(38) Inactivating mutations of Rnf43 were related to Wnt dependency.”
BackgroundStructural and Druggability Landscape of Frizzled G Protein-Coupled Receptors
Zhang, X., Dong, S., & Xu, F. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.09.002 · Cited by 55 · cited 1×
“For Fzds family, it owns at least 10 members of G protein-coupled receptor (GPCR).(16) The highly conserved cysteine-rich domain (CRD) of Fzds manipulates the ligand recognition and binding.”
BackgroundWu, W., Zhu, H., Fu, Y., Shen, W., Miao, K., Hong, M. J., Xu, W., Fan, L., Young, K. H., Liu, P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7795 · Cited by 55
Activation of the Wnt pathway through Wnt2 promotes metastasis in pancreatic cancer.
Jiang, H., Li, Q., He, C., Li, F., Sheng, H., Shen, X., Zhang, X., Zhu, S., Chen, H., Chen, X.-M., et al. (2014) · Europe PMC (PubMed Central) · Cited by 54
Self-citationBernkopf, D. B., Brückner, M., Hadjihannas, M. V., & Behrens, J. (2019) · Nature Communications · doi:10.1038/s41467-019-12203-8 · Cited by 54 · cited 2×
“Controlling Axin polymerization may be a potential therapeutic choice to suppress cancer development.(154,155) Mutations of AxinCR were reported to accelerate the tumorigenesis in the following cancers: HCC, colorectal adenomas, ovarian carcinomas, lung carcinomas, and sporadic medulloblastomas.”
BackgroundNygren, M. K., Døsen, G., Hystad, M. E., Stubberud, H., Funderud, S., & Rian, E. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06442.x · Cited by 54 · cited 1×
“In leukemia, a study indicated that Wnt3a, activating Wnt/β-catenin, suppressed the proliferation of cancer cells.(75) Therapeutically, in prostate cancers, targeting Wnt3a through Traf6 either Tmem64 restrained tumor development.”
BackgroundLi, X., Pu, J., Jiang, S., Su, J., Kong, L., Mao, B., Sun, H., & Li, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068525 · Cited by 53
Eto, T., Miyake, K., Nosho, K., Ohmuraya, M., Imamura, Y., Arima, K., Kanno, S., Fu, L., Kiyozumi, Y., Izumi, D., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5098 · Cited by 53 · cited 13×
“Znrf3 and Rnf43 were not essential in the intestine but dysregulation of Znrf3/Rnf43 was important for the growth of CRC.(26,27,123) Mutations of Rnf43, resulting in E3 ubiquitin ligases function loss, promoted CRC development and poor prognosis.”
BackgroundInfluentialVenerando, A., Girardi, C., Ruzzene, M., & Pinna, L. A. (2013) · Biochemical Journal · doi:10.1042/bj20121140 · Cited by 53 · cited 6×
“Just as mentioned above, as an antiparasitic agent pyrvinium also inhibited Wnt/β-catenin pathway via activating CK1α, or Gsk3β.(194,361) Other old drugs like niclosamide to inhibit canonical Wnt signaling by promoting Fzd1 endocytosis,(404) celecoxib to induce the degradation of Tcf7,(405) and salinomycin to target L…”
BackgroundInfluentialInhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer
Doo, D. W., Meza-Perez, S., Londoño, A. I., Goldsberry, W. N., Katre, A. A., Boone, J. D., Moore, D. J., Hudson, C. T., Betella, I., McCaw, T. R., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920913798 · Cited by 52 · cited 1×
“LGK974 also preliminarily demonstrated a reliable tumor-suppressive effect in vitro on neuroendocrine tumor and ovarian cancer.(286,287) A study using uncovered similar impairment of bone mass in two different doses of LGK974 in mice (3 and 6mg/kg/d for 7 days).”
BackgroundSOX10 is a novel oncogene in hepatocellular carcinoma through Wnt/β-catenin/TCF4 cascade
Dangjun, Z., Bai, F., Zhang, X., Hu, M., Zhao, G., Zhao, Z., & Liu, R. (2014) · Tumor Biology · doi:10.1007/s13277-014-1893-1 · Cited by 52
Kang, D. W., & Min, D. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012109 · Cited by 52
Wang, J., Wang, C.-L., Wen, J., Wang, Y., Hu, Y., & Ren, H. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.3982 · Cited by 52
Self-citationWang, Y., Zhang, W., Wang, Y., & Wang, S. (2018) · PubMed · Cited by 52
Self-citationIdentification of RSPO2 Fusion Mutations and Target Therapy Using a Porcupine Inhibitor
Li, C., Cao, J., Zhang, N., Tu, M., Xu, F., Wei, S., Chen, X., & Xu, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-32652-3 · Cited by 51 · cited 2×
“For experimental analysis, it has been discovered for a good performance in CRC with fused Rspo.(291) Further in-depth studies respectively included the combined usage of CGX1321 and immune checkpoint blockade therapy to treat ovarian cancer (but the results were unsatisfactory),(292) and liposome encapsulation as a v…”
BackgroundLi, S., Lavrijsen, M., Bakker, A., Magierowski, M., Magierowska, K., Liu, P., Wang, W., Peppelenbosch, M. P., & Smits, R. (2020) · Oncogene · doi:10.1038/s41388-020-1232-5 · Cited by 50 · cited 3×
“For instance, the R-spondins (Rspo), member 1/2/3/4,20 which coordinates with leucine-rich repeat-containing GPCR (Lgr) 4/ 5/6 to enhance Wnt/β-catenin signaling.21–24 Specifically, the Rspo-Lgr complex increases Lrp5/6 phosphorylation and inactivates Wnt repressors Rnf43 and Znrf3.”
BackgroundCheng, D., Liu, J., Han, D., Zhang, G., Gao, W., Hsieh, M. H., Ng, N., Kasibhatla, S., Tompkins, C., Li, J., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00038 · Cited by 50 · cited 3×
“GNF-1331 is a precursor drug, and the optimization of it brings on the discoveries of LGK974 and GNF6231.”
BackgroundInfluentialLee, S.-B., Park, Y. I., Dong, M., & Gong, Y. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.07.088 · Cited by 50
Variations in AXIN2 predict risk and prognosis of colorectal cancer
Otero, L., Lacunza, E., Vasquez, V. M., Arbeláez, V., Cardier, F., & González, F. (2019) · BDJ Open · doi:10.1038/s41405-019-0022-z · Cited by 50
Wall, J. A., Meza-Perez, S., Scalise, C. B., Katre, A., Londoño, A. I., Turbitt, W. J., Randall, T., Norian, L. A., & Arend, R. C. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.10.031 · Cited by 50
Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro
Kunnimalaiyaan, S., Schwartz, V. K., Jackson, I. A., Gamblin, T. C., & Kunnimalaiyaan, M. (2018) · BMC Cancer · doi:10.1186/s12885-018-4474-7 · Cited by 50 · cited 1×
“LY2090314 is a potent Gsk3α/β inhibitor that has demonstrated good cooperation with platinum agents in vitro in the treatment of melanoma,(363) AR-V7 prostate cancer,(364) and neuroblastoma.(365) But in a phase I clinical trial, the combination of LY2090314 and pemetrexed/carboplatin showed eleven DLTs in ten enrolled…”
BackgroundSolberg, N. T., Waaler, J., Lund, K., Mygland, L., Olsen, P. A., & Krauss, S. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0362 · Cited by 49 · cited 1×
“As an adjuvant, G007-LK can also enhance the sensitivity of glioma stem cells to a chemo drug temozolomide and CRC cells to PI3K/EGFR inhibitors.(339,340) As mentioned above, IWR compounds were defined based on their anti-Wnt pathway activities in a phenotypic screening assay.”
BackgroundTRAF6 function as a novel co-regulator of Wnt3a target genes in prostate cancer
Aripaka, K., Gudey, S. K., Zang, G., Schmidt, A., Åhrling, S. S., Österman, L., Bergh, A. R. J., von Hofsten, J., & Landström, M. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.06.046 · Cited by 49 · cited 1×
“Therapeutically, in prostate cancers, targeting Wnt3a through Traf6 either Tmem64 restrained tumor development.(76,77) For liver cancers, targeting Wnt3a by miRNA-195 and miRNA‐214 presented the possibility of cancer management.”
BackgroundmiR-135b reverses chemoresistance of non-small cell lung cancer cells by downregulation of FZD1
Su, W., Mo, Y., Wu, F., Guo, K., Li, J., Luo, Y., Ye, H., Guo, H., Li, D., & Yang, Z. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.09.027 · Cited by 49
Emergence of TNIK inhibitors in cancer therapeutics
Yamada, T., & Masuda, M. (2017) · Cancer Science · doi:10.1111/cas.13203 · Cited by 48
Zhang, C., & Wang, Y. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9765 · Cited by 48
Self-citationThe Antihelmintic Drug Pyrvinium Pamoate Targets Aggressive Breast Cancer
Xu, W., Lacerda, L., Debeb, B. G., Atkinson, R. L., Solley, T. N., Li, L., Orton, D., McMurray, J. S., Hang, B. I., Lee, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071508 · Cited by 47
Gui, S., Yuan, G., Wang, L., Zhou, L., Xue, Y., Yu, Y., Zhang, J., Zhang, M., Yang, Y., & Wang, D. W. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24490 · Cited by 47
Zhang, H., Jing, X., Wu, X., Hu, J., Zhang, X., Wang, X., Su, P., Li, W., & Zhou, G. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000236 · Cited by 47
Porcupine inhibitors impair trabecular and cortical bone mass and strength in mice
Funck-Brentano, T., Nilsson, K. H., Brommage, R., Henning, P., Lerner, U. H., Koskela, A., Tuukkanen, J., Cohen-Solal, M., Movérare-Skrtic, S., & Ohlsson, C. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0153 · Cited by 47 · cited 3×
“However, when administrated at 10mg/kg/d for 7 or 21 days, bone loss was observed in mice.(281) This should be taken into consideration as the potential side effect of WNT-C59 in cancer therapies.”
BackgroundMethodGabata, R., Harada, K., Mizutani, Y. H., Ouchi, H., Yoshimura, K., Sato, Y., Kitao, A., Kimura, K., Kouji, H., Miyashita, T., et al. (2020) · Anticancer Research · doi:10.21873/anticanres.14524 · Cited by 47
Inhibition of Wnt/β-Catenin Signaling in Neuroendocrine Tumors In Vitro: Antitumoral Effects
Jin, X., Spöttl, G., Maurer, J., Nölting, S., & Auernhammer, C. J. (2020) · Cancers · doi:10.3390/cancers12020345 · Cited by 47 · cited 2×
“Their preclinical efficiency has been demonstrated in a variable of cancer cells such as HNSCC,(301) hepatoma carcinoma,(390) and neuroendocrine tumor cells.(286) A clinical trial of cancer research is still engaging but without results posted (Table 2, two of the three trials were terminated).”
BackgroundPimozide suppresses colorectal cancer via inhibition of Wnt/β-catenin signaling pathway
Ren, Y., Tao, J., Jiang, Z., Guo, D., & Tang, J. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.08.027 · Cited by 45
Axin cancer mutants form nanoaggregates to rewire the Wnt signaling network
Anvarian, Z., Nojima, H., van Kappel, E. C., Madl, T., Spit, M., Viertler, M., Jordens, I., Low, T. Y., van Scherpenzeel, R. C., Kuper, I., et al. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3191 · Cited by 45 · cited 1×
“Inhibition of Axin and Apc complex together promoted tumor genesis and progression by enhancing Wnt/β-catenin signaling.(153,154) Controlling Axin polymerization may be a potential therapeutic choice to suppress cancer development.”
BackgroundmiR-1247-5p functions as a tumor suppressor in human hepatocellular carcinoma by targeting Wnt3
Chu, Y., Fan, W., Guo, W., Zhang, Y., Wang, L., Guo, L., Duan, X., Wei, J., & Xu, G. (2017) · Oncology Reports · doi:10.3892/or.2017.5702 · Cited by 45 · cited 3×
“In this figure, we do not distinguish the autocrine or paracrine patterns of Wnt ligands Signal Transduction and Targeted Therapy (2021) 6:307 knockdown of Wnt3 could increase drug sensitivity.64,65 In prostate cancer, inhibiting Wnt3 signaling by the deficiency of trophinin-associated protein attenuated the cancer gr…”
BackgroundLRP6 promotes invasion and metastasis of colorectal cancer through cytoskeleton dynamics
Yao, Q., An, Y., Hou, W., Cao, Y.-N., Yao, M., Ma, N., Hou, L., Zhang, H., Liu, H., & Zhang, B. (2017) · Oncotarget · doi:10.18632/oncotarget.22759 · Cited by 44
Yang, Y., LI, M., Chang, S., Wang, L., Song, T., Gao, L., Hu, L., Li, Z., Liu, L., Yao, J., et al. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2526 · Cited by 44 · cited 1×
“For liver cancers, targeting Wnt3a by miRNA-195 and miRNA‐214 presented the possibility of cancer management.(78,79)”
BackgroundVerkaar, F., van der Doelen, A. A., Smits, J. F. M., Blankesteijn, W. M., & Zaman, G. J. R. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.01.015 · Cited by 43
Deng, Y., Su, Q., Mo, J., Fu, X., Zhang, Y., & Lin, E. H. (2013) · Cancer Investigation · doi:10.3109/07357907.2012.754458 · Cited by 43
Kleszcz, R., Szymańska, A., Krajka‐Kuźniak, V., Baer‐Dubowska, W., & Paluszczak, J. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00440-4 · Cited by 43 · cited 3×
“A similar situation occurred in HNSCC cells as well.(301)”
BackgroundQuackenbush, K. S., Bagby, S., Tai, W. M., Messersmith, W. A., Schreiber, A., Greene, J., Kim, J., Wang, G., Purkey, A., Pitts, T. M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8626 · Cited by 43
Aristizábal-Pachón, A. F., de Carvalho, T. I., Carrara, H. H. A., de Andrade, J. M., & Takahashi, C. S. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.16.7277 · Cited by 43
Prognostic significance of Traf2- and Nck- interacting kinase (TNIK) in colorectal cancer
Takahashi, H., Ishikawa, T., Ishiguro, M., Okazaki, S., Mogushi, K., Kobayashi, H., Iida, S., Mizushima, H., Tanaka, H., Uetake, H., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1783-y · Cited by 42 · cited 1×
“And patients with overexpression of Tnik were manifested with poor postsurgical outcomes.(253) Over 80% of CRCs have mutations in Apc,(254) which makes the only molecule downstream of Apc a therapeutic target.”
BackgroundMonin, M. B., Krause, P., Stelling, R., Bocuk, D., Niebert, S., Klemm, F., Pukrop, T., & Koenig, S. (2016) · Journal of Surgical Research · doi:10.1016/j.jss.2016.03.051 · Cited by 42
Pharmacological inhibition of tankyrase induces bone loss in mice by increasing osteoclastogenesis
Fujita, S., Mukai, T., Mito, T., Kodama, S., Nagasu, A., Kittaka, M., Sone, T., Ueki, Y., & Morita, Y. (2017) · Bone · doi:10.1016/j.bone.2017.10.017 · Cited by 42 · cited 2×
“times higher than that of osteoclasts.(326) Not only Tnks, but the family of PARP plays an important role in bone homeostasis.”
BackgroundLi, H. K., Sugyo, A., Tsuji, A. B., Morokoshi, Y., Minegishi, K., Nagatsu, K., Kanda, H., Harada, Y., Nagayama, S., Katagiri, T., et al. (2018) · Cancer Science · doi:10.1111/cas.13636 · Cited by 41 · cited 1×
“In addition, mAbs can serve as the vehicle to achieve precision medicine, such as targeting radiogen to tumors.(275) To sum up, in practical scenarios, mAbs are more competent for the treatment of hematological tumors than solid tumors as a consequence of their antigenicity and large particles.”
BackgroundLi, C., Liang, Y., Cao, J., Zhang, N., Wei, X., Tu, M., Xu, F., & Xu, Y. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.06.013 · Cited by 39 · cited 1×
“Further in-depth studies respectively included the combined usage of CGX1321 and immune checkpoint blockade therapy to treat ovarian cancer (but the results were unsatisfactory),(292) and liposome encapsulation as a vehicle to deliver CGX1321 to treat cancer stem cells (with expected results).(293) As for the clinical…”
BackgroundZhang, M., Wang, Z., Zhang, Y., Guo, W., & Ji, H. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00068 · Cited by 39 · cited 1×
“Indeed, the SMI 40-fluoro-Nphenyl-[1,10-biphenyl]−3-carboxamide and its derivatives showed a much greater affinity toward β-catenin/BCL9 over β-catenin/E-cadherin.(389) For targeting CBP, PRI-724, and ICG-001, a pair of enantiomers, are potent inhibitors of canonical Wnt signaling that antagonize the binding of β-cate…”
BackgroundMojsin, M. M., Marjanović, J., Schwirtlich, M., Topalović, V., & Stevanović, M. J. (2014) · Food & Function · doi:10.1039/c4fo00484a · Cited by 39
Anti-tumor effects of fibroblast growth factor-binding protein (FGF-BP) knockdown in colon carcinoma
Schulze, D., Plohmann, P., Höbel, S., & Aigner, A. M. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-144 · Cited by 39
RUNX3 inhibits glioma survival and invasion via suppression of the β-catenin/TCF-4 signaling pathway
Sun, J., Li, B., Jia, Z., Zhang, A., Wang, G., Chen, Z., Shang, Z., Zhang, C., Cui, J., & Yang, W. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2927-0 · Cited by 38 · cited 1×
“RUNX3 inhibited Wnt/β-catenin signaling by comprising of a ternary complex with β-catenin–Tcf and attenuates growth and progression of multiple cancers, especially in gastric cancer.(242,243) SOX4 can increase β-catenin–Lef/Tcf transcriptional activity through upregulating Tcf4.”
BackgroundFZD5 prevents epithelial-mesenchymal transition in gastric cancer
Dong, D. F., Lei, N., Zhou, K., Wang, Z., Sun, Y., Zheng, Q., Gao, J., Zhao, C., & Wang, W. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00708-z · Cited by 38
Role of WNT5A receptors FZD5 and RYK in prostate cancer cells
Thiele, S., Zimmer, A., Göbel, A., Rachner, T. D., Rother, S., Fuessel, S., Froehner, M., Wirth, M. P., Muders, M. H., Baretton, G. B., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25551 · Cited by 38 · cited 1×
“Also, Fzd4 and Fzd5 were reported to be significantly increased in prostate cancer.(92,93) Fzd6 highly emerged in CRC, breast cancer, and bladder cancer.”
BackgroundHuang, J., Qu, Q., Guo, Y., Xiang, Y., & Feng, D. (2020) · Journal of Cancer · doi:10.7150/jca.30976 · Cited by 38 · cited 2×
“For instance, NVPTNKS656 increased the sensitivity of CRC cells to PI3K/AKT inhibitor in vivo, but the increment effect could be reversed by high FOXO3A.(346) And NVP-TNKS656 also inhibited the metastatic and invasive EMT hallmarks of hepatoma carcinoma cells.”
BackgroundTROAP regulates prostate cancer progression via the WNT3/survivin signalling pathways
Ye, J., Chu, C., Chen, M., Shi, Z., Gan, S., Qu, F., Pan, X., Yang, Q., Tian, Y., Wang, L., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6854 · Cited by 37 · cited 2×
“In prostate cancer, inhibiting Wnt3 signaling by the deficiency of trophinin-associated protein attenuated the cancer growth.(66) The demethylation of non-coding RNA miR-1247-5p provided an optional remedy for human hepatocellular carcinoma (HCC) via inhibiting Wnt3.”
BackgroundTankyrase Inhibitors as Therapeutic Targets for Cancer
Kamal, A., Riyaz, S., Srivastava, A. K., & Rahim, A. (2014) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026614666140929115831 · Cited by 36
Tankyrase (PARP5) Inhibition Induces Bone Loss through Accumulation of Its Substrate SH3BP2
Mukai, T., Fujita, S., & Morita, Y. (2019) · Cells · doi:10.3390/cells8020195 · Cited by 36
(2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0763-1 · Cited by 36
Lee, R. S., Zhang, L., Berger, A., Lawrence, M. G., Song, J., Niranjan, B., Davies, R. G., Lister, N. L., Sandhu, S. K., Rubin, M. A., et al. (2019) · Neoplasia · doi:10.1016/j.neo.2019.02.005 · Cited by 35 · cited 1×
“In addition to CRC, inhibitory effects of NCB drugs have also been reported in other tumors.(378,379) Inhibitors targeting β-catenin–-Lef/Tcf complex.”
BackgroundOral supplementation of silibinin prevents colon carcinogenesis in a long term preclinical model
Nagarajan, S., Aranganathan, S., Panneerselvam, J., Shanthi, P., Gopalan, R., & Nalini, N. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.05.060 · Cited by 35 · cited 1×
“Moreover, silibinin, an extract from the milk thistle seeds, also showed its potentiality in preventing tumorigenesis in a preclinical model.(402,403) In addition to natural products, many FDA-approved drugs have expanded their indications to crosstalk with Wnt/β-catenin signaling.”
BackgroundHirakawa, T., Nasu, K., Miyabe, S., Kouji, H., Katoh, A., Uemura, N., & Narahara, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-56302-4 · Cited by 35 · cited 1×
“However, they seemed to be more applicable in antifibrosis than in antitumor.(391,392) BCL9 provides an excellent opportunity for targeting Wnt signaling therapy.”
BackgroundBahl, C., Sharma, S., Singh, N., & Behera, D. (2017) · Tumor Biology · doi:10.1177/1010428317695533 · Cited by 35
Nie, X., Xia, F., Liu, Y., Zhou, Y., Ye, W., Hean, P., Meng, J., Liu, H., Liu, L., Wen, J.-X., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01110 · Cited by 34 · cited 14×
“The constitutive activation form of β-catenin, the exon 3 mutations, is believed to regulate the Signal Transduction and Targeted Therapy (2021) 6:307 genesis of hereditary non-polyposis CRC.208 In CRC, there are several mutations of β-catenin, leading to abnormally activated Wnt/β-catenin signaling.209 The mutations…”
BackgroundInfluentialSelf-citationBufalin inhibits gastric cancer invasion and metastasis by down-regulating Wnt/ASCL2 expression
Wang, J., Cai, H., Xia, Y., Wang, S., Xing, L., Chen, C., Zhang, Y., Xu, J., Yin, P., Jiang, Y., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24157 · Cited by 34 · cited 1×
“In gastric cancer, XAV939 can inhibit the invasion and metastasis of cancer cells.(331) XAV939 and RNAi-Tnks1 inhibited the stemness and migration of cancer stem cells and accelerated cell apoptosis in neuroblastoma by attenuating the abnormal status of Wnt/β-catenin signaling.”
BackgroundWnt2 contributes to the progression of gastric cancer by promoting cell migration and invasion
Zhang, Z., Wang, J., & Dong, X. (2018) · Oncology Letters · doi:10.3892/ol.2018.9050 · Cited by 34
Hughes, T. A., & Brady, H. J. M. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.03.026 · Cited by 33
Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia
Khan, A. S., Hojjat‐Farsangi, M., Daneshmanesh, A. H., Hansson, L., Kokhaei, P., Österborg, A., Mellstedt, H., & Moshfegh, A. (2016) · Tumor Biology · doi:10.1007/s13277-016-5039-5 · Cited by 33 · cited 1×
“peripheral blood mononuclear cells, Dvl1-3 were found to be exclusively expressed in NSCLC and CLL cells, respectively.(368,369) Most drugs targeting Dvls currently are developed to selectively inhibit PDZ-Fzd interaction.”
BackgroundFarahmand, L., Darvishi, B., Majidzadeh-A, K., & Ansari, A. M. (2017) · Cell Proliferation · doi:10.1111/cpr.12299 · Cited by 33 · cited 1×
“The crosstalk of Shh-Wnt/β-catenin involves the relapse, invasion, and metastasis of certain cancers, so that the repression of this crosstalk may alleviate the progression, migration, and invasion of cancers.(269) For instance, cyclopamine, as an inhibitor of Shh signaling, postpones the invasion of CRC by suppressin…”
Background
Research works printed but not linked: 4
- Schwarz-Romond T The DIX domain of Dishevelled confers Wnt signaling by dynamic polymerization Nat. Struct. Mol. Biol. 2007 14 484 492 10.1038/nsmb1247 17529994 · DOI · Paper page
- Hoey, T. (ed.) Development of FZD8-Fc (OMP-54 F28), aWnt signaling antagonist that inhibits tumor growth and reduces tumor initiating cell frequency. Presented at AACR Annual Meeting; 2013 April; Washington DC (2013).
- OncoMed Pharmaceuticals, Inc. A phase 1b dose escalation study of vantictumab (OMP-18R5) in combination with nab-paclitaxel and gemcitabine in patients with previously untreated stage IV pancreatic cancer. NCT02005315, 18R5-003R5. PMC7211194 31338636
- OncoMed Pharmaceuticals, Inc. A phase 1b dose escalation study of OMP-54F28 in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. NCT02092363, 54F28-003. PMC7397408 31174889
Cited by
Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets
Di, X., Gao, X., Peng, L., Ai, J., Jin, X., Qi, S., Li, H., Wang, K., & Luo, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01501-9 · Cited by 622
Research progress of glutathione peroxidase family (GPX) in redoxidation
Pei, J., Pan, X., Wei, G., & Hua, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1147414 · Cited by 617
“In the Wnt pathway, the key step of the Wnt pathway is the binding of the Wnt protein to the Frizzled receptor, and the nuclear redox protein (NRX) blocks Disheveled (DVL) and plays a negative regulatory role in the Wnt pathway (Yu et al., 2021).”
Background(2023) · doi:10.1038/s41392-022-01304-4 · Cited by 460
Self-citationWnt/β-catenin signaling pathway in carcinogenesis and cancer therapy
Song, P., Gao, Z., Bao, Y., Chen, L., Huang, Y., Liu, Y., Dong, Q., & Wei, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01563-4 · Cited by 382
“Consequently, extensive research has demonstrated the ability of rosmantuzumab to impede self-renewal and differentiation processes in acute myeloid leukemia cells within PDX models, while simultaneously preserving the normal physiological function of hematopoietic stem cells [347].”
BackgroundRole of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications
Zhao, L.-Y., Mei, J.-X., Yu, G., Lei, L., Zhang, W.-H., Liu, K., Chen, X.-L., Kołat, D., Yang, K., & Hu, J.-K. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01406-7 · Cited by 359
“Specifically, FadA binds to E-cadherin on the membrane, leading to the phosphorylation and internalization of E-cadherin, which is accompanied by increased β-catenin release and translocation into the nucleus due to the degradation of the E-cadherin/ β-catenin complex, resulting in the aberrant activation of Wnt signa…”
Background
Metadata
- Authors
- Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L.
- Affiliations
- Sichuan University (CN)
- Corresponding author
- Ye, Ling
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2021-08-30
- Volume
- 6
- Issue
- 1
- Pages
- 307-307
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC8403677
- OpenAlex
- W3198051187
- Cited by
- 734
- References
- 468
- Citations by year
- 2026: 106 · 2025: 234 · 2024: 200 · 2023: 139 · 2022: 53 · 2021: 2
- FWCI
- 10.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81825005)
- State Key Laboratory of Oral Disease
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- Wnt/β-catenin signaling, cancer, targeted therapy, aberrant signaling, malignant progression, prognosis, clinical translation, treatment resistance
- MeSH terms
- Humans, Neoplasm Proteins, Neoplasms, Wnt Proteins, beta Catenin, Wnt Signaling Pathway
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.